Scrip
>>Business

McKinsey Exec On Technology Trends Reshaping Future Factories

09 Mar 2022

McKinsey senior partner Joseph Hughes outlines the shape of things to come as new technologies transform life sciences manufacturing, while new modalities around cell-, gene- and RNA-based therapeutics could have “profound implications” on global operations networks.

advanced manufacturing — New Technologies Are Set To Transform Life Sciences Manufacturing • Source: Alamy

The new technology-enabled revolution, one that is being driven by connectivity, data, analytics and automation, is expected to transform future factories dramatically and disrupt the next decade, while potentially bringing with it sharp gains across multiple metrics for the life sciences industry.

Addressing the Global Pharmaceutical Quality Summit 2022, Joseph Hughes, senior partner, Global Leader Life Sciences Operations and Quality Practice, McKinsey...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

25 Jun 2025

• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

25 Jun 2025

• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

25 Jun 2025

• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

25 Jun 2025

• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.